Log in Free sign up

Marinus Pharmaceuticals (MRNS) News and press releases

News

From Benzinga Pro

Recap: Marinus Pharma Q1 Earnings

Marinus Pharma (NASDAQ:MRNS) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Marinus Pharma beat estimated earnings by 38.82%, reporting an EPS of $-0.52 versus an estimate of $-0.85.

Marinus Pharmaceuticals Q1 EPS $(0.52) Beats $(0.85) Estimate, Sales $14.19M Up From $1.81M YoY

Marinus Pharmaceuticals (NASDAQ:MRNS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.85) by 38.82 percent. This is a 29.73 percent increase over losses of $(0.74) per

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

Biotech, Earnings, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Earnings Scheduled For May 12, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 807 companies reached new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Thursday, 351 stocks hit new 52-week lows.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Marinus Pharmaceuticals Announces Resumption Of Phase 3 RAISE Trial In Status Epilepticus

Biotech, News, FDA, General

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening and recruitment for

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Wednesday's trading, 435 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Wednesday's session saw 784 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Tuesday, 242 companies hit new 52-week lows.

Marinus Pharmaceuticals Announced Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results; Said Results Demonstrate Safety and Efficacy of ZTALMY for Seizures Associated with CDKL5 Deficiency Disorder in Patients Two Years and Older

News, Small Cap

Marinus Pharmaceuticals, Inc.

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, Top Stories, Trading Ideas, General

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.

Analyzing Marinus Pharmaceuticals Inc's Short Interest

Short Sellers, Short Ideas, Trading Ideas

Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) short percent of float has risen 9.74% since its last report. The company recently reported that it has 1.23 million shares sold short, which is 3.83% of all regular shares that are available for trading.

Truist Securities Maintains Buy on Marinus Pharmaceuticals, Raises Price Target to $50

News, Price Target, Analyst Ratings

Truist Securities analyst Joon Lee maintains Marinus Pharmaceuticals (NASDAQ:MRNS) with a Buy and raises the price target from $35 to $50.

JMP Securities Maintains Market Outperform on Marinus Pharmaceuticals, Raises Price Target to $22

News, Price Target, Analyst Ratings

JMP Securities analyst Jason Butler maintains Marinus Pharmaceuticals (NASDAQ:MRNS) with a Market Outperform and raises the price target from $21 to $22.

SVB Leerink Maintains Outperform on Marinus Pharmaceuticals, Lowers Price Target to $27

News, Price Target, Analyst Ratings

SVB Leerink analyst Marc Goodman maintains Marinus Pharmaceuticals (NASDAQ:MRNS) with a Outperform and lowers the price target from $30 to $27.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.

Press releases

From Benzinga Pro

Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

ZTALMY® (ganaxolone) U.S. commercial launch on track for July 2022 Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 15 new

Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening and recruitment for

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of an inducement award to one new

Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Results demonstrate safety and efficacy of ZTALMY, first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients two years and older Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a

Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility

BARDA research contract extended through 2023 Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Received FDA approval of ZTALMY® (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder; first approved treatment for this rare form of genetic epilepsy Awarded a Rare Pediatric

Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder

First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older1 ZTALMY significantly reduced major motor seizure frequency in CDD patients in

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to three new